Philippe Menu Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $5.66, for a total transaction of $28,300.00. Following the completion of the sale, the insider owned 223,387 shares of the company’s stock, valued at approximately $1,264,370.42. This represents a 2.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.95, for a total transaction of $24,750.00.

SOPHiA GENETICS Stock Performance

Shares of SOPH opened at $5.55 on Thursday. The stock has a fifty day moving average price of $5.44 and a 200-day moving average price of $5.09. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 12 month low of $2.92 and a 12 month high of $6.77. The firm has a market cap of $465.59 million, a PE ratio of -10.67 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%. Equities research analysts predict that SOPHiA GENETICS SA will post -0.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

SOPH has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, HC Wainwright began coverage on SOPHiA GENETICS in a research report on Monday, July 20th. They issued a “buy” rating and a $12.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average target price of $9.00.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Perkins Capital Management Inc. purchased a new position in SOPHiA GENETICS in the 4th quarter valued at approximately $49,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS during the third quarter worth about $49,000. First Dallas Securities Inc. purchased a new stake in SOPHiA GENETICS in the first quarter valued at approximately $50,000. Quadrature Capital Ltd acquired a new position in shares of SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter valued at $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.